3 Best Stocks to Buy Now, 9/12/2025 - Top Analysts Reveal Their Picks

Wall Street's sharpest minds just dropped their hottest takes—and these three names keep surfacing.

The Consensus Picks

Forget the noise. Top analysts are converging on three standout equities that promise serious upside. No fluff, just data-driven conviction from the pros who actually read the fine print.

Timing the Market? Don't Bother.

While day traders chase headlines, institutional money moves on research. These picks reflect deep fundamental analysis, not reactive hype. Because let's be honest—most 'market insights' are just recycled predictions from last quarter's earnings call.

Positioning for Q4 Dominance

Each selection targets sectors poised for explosive growth through year-end. We're talking infrastructure, tech innovation, and consumer resilience—the trifecta for weathering whatever economic drama comes next.

Bottom line: If you're still listening to FinTwit for stock tips, maybe reconsider your sources. Actual analysts actually doing actual work? Now that's a concept.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts. 

Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.

 (NVDA) – Nvidia is a semiconductor company known for its GPUs, widely used in gaming, data centers, and artificial intelligence. Today, Jefferies analyst Blayne Curtis maintained a Buy rating on the stock. Interestingly, 36 out of the 38 Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 20.80%.

(AVTX) – Avalo Therapeutics is a clinical-stage biotech developing therapies for immune and inflammatory diseases. YesterdayPiper Sandler analyst Yasmeen Rahimi maintained a Buy rating on the stock with a price target of $48 per share. In the last three months, all four Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 279.87%.

(ENVX) – Enovix is a battery company developing high-energy silicon-anode cells for electronics. Yesterday, Craig-Hallum analyst George Sutton maintained a Buy rating on the stock. In the last three months, all six Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 203.13%.

Who Are the Top Analysts? 

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time.